Drugs which have limited access and are used treat rare diseases, are called "orphan drugs".
The reason why these drugs are called "orphan" is that the pharmaceutical industry has little interest in developing and marketing these drugs which are used only for a low number of patient groups This is because pharmaceutical companies cannot compensate the very high cost of developing these drugs. In this review article it is aimed to give information about orphan drugs, policies about these drugs and difficulties to reach them.
Birincil Dil | İngilizce |
---|---|
Konular | Eczacılık İşletmeciliği |
Bölüm | Review Articles |
Yazarlar | |
Yayımlanma Tarihi | 3 Ocak 2024 |
Gönderilme Tarihi | 19 Temmuz 2023 |
Kabul Tarihi | 10 Ekim 2023 |
Yayımlandığı Sayı | Yıl 2023 Cilt: 40 Sayı: 4 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.